Kolexia
Saad Alain Hématologie
Saad Alain
Hématologie
Centre Hospitalier de Beziers
Béziers, France
81 Activités
4 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Lymphomes Lymphome T Lymphome T cutané Lymphome T périphérique Thrombose Récidive tumorale locale

Collaborateurs

Voir plus
Altamiranda Sergio
Altamiranda Sergio
Centre Hospitalier de Beziers, Béziers, France
Drebit Yuriy
Drebit Yuriy
Centre Hospitalier de Beziers, Béziers, France
David Selva
David Selva
Centre Hospitalier de Lodeve, Lodève, France
Almeras Marion
Almeras Marion
Centre Hospitalier de Beziers, Béziers, France

Industries

Voir plus
A+A
232 collaboration(s)
Dernière en 2023
B3TSI
136 collaboration(s)
Dernière en 2023
IQVIA
116 collaboration(s)
Dernière en 2023
M3 Global Research Ltd
100 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
ALFA2101: An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Essai Clinique (CHU Nice)   29 janvier 2024
Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Essai Clinique (CHU Brest)   27 octobre 2023
LAMSA2020: A Phase II Randomized Study to Assess the Efficacy on Outcome of Venetoclax Combined With Cytarabine Versus Idarubicin Combined With Cytarabine Administered as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission
Essai Clinique (French Innovative Leukemia Organisation)   07 septembre 2023
Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study
Annual Meeting Abstracts 2022   15 novembre 2022
Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group
Annual Meeting Abstracts 2022   15 novembre 2022
Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania.
Annals of hematology   12 mars 2022
Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group
Blood   23 novembre 2021
Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group
Blood   05 novembre 2020
BIG-1: Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial
Essai Clinique (CHU Angers)   16 octobre 2020